Memorial Sloan Kettering Cancer Center
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Phase 2
Completed
- Conditions
- Neuroblastoma
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00089258
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Phase 2
Completed
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00089167
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
Phase 1
Completed
- Conditions
- Kidney Cancer
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00003542
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003539
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus
Phase 2
Completed
- Conditions
- Esophageal Cancer
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00003087
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Completed
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00003358
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
Phase 2
Completed
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2004-07-30
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003055
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy in Treating Patients With Retinoblastoma
Phase 2
Completed
- Conditions
- Retinoblastoma
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00002675
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 1
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005633
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
Phase 3
Completed
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmLeukemiaFatigueMyelodysplastic SyndromesChronic Myeloproliferative DisordersLymphomaPrecancerous ConditionUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005805
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath